1. AB0160 Effects of TOFACITINIB (CP-690, 550) on lipid biomarkers in rat adjuvant-induced arthritis (AIA) model and in patients with active rheumatoid arthritis. (23rd January 2014) Authors: McInnes, I.; Kaplan, I.; Boy, M.; Riese, R.; Zuckerman, A.; Clark, J.; Kishore, N.; Brosnan, M.; Zwillich, S.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 646 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0595 Changes in serum creatinine in patients with active rheumatoid arthritis treated with TOFACITINIB (CP-690, 550). (23rd January 2014) Authors: Isaacs, J.; Nduaka, C.; Zuckerman, A.; Krishnaswami, S.; Riese, R.; Lan, S.; Hutmacher, M.; Boy, M.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0724 Safety, pharmacokinetics, and pharmacodynamics of a human anti-IL6 monoclonal antibody PF-04236921 in healthy subjects. (23rd January 2014) Authors: Fogel, R.; Sridharan, S.; Li, C.; Bradley, J.; Riese, R.; Labadie, R.; Menon, S.; Gupta, P.; Krishnasawami, S.; Beebe, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0137 Effects of tofacitinib on lipid biomarkers in patients with active rheumatoid arthritis. (23rd January 2014) Authors: McInnes, I. B.; Kaplan, I.; Boy, M.; Riese, R.; Zuckerman, A.; Gruben, D.; Brosnan, M. J.; Zwillich, S.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0178 Estimated Medical Expenditures among Patients with Rheumatoid Arthritis Undergoing Treatment with Tofacitinib, an Oral Janus Kinase Inhibitor. (10th June 2014) Authors: Rendas-Baum, R.; Kosinski, M.; Singh, A.; Mebus, C.; Wilkinson, B.; Riese, R.; Wallenstein, G. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 446 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP0154 Integrated Safety Analysis of Tofacitinib in RA Clinical Trials with A Cumulative Exposure of 12, 664 Patient-Years. (10th June 2014) Authors: Cohen, S.; Tanaka, Y.; Mariette, X.; Curtis, J.; Kwok, K.; Lee, E.; Nash, P.; Winthrop, K.; Charles-Schoeman, C.; Thirunavukkarasu, K.; Anisfeld, A.; Wang, L.; Riese, R.; Wollenhaupt, J. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OP0163 Evaluation of Influenza and Pneumococcal Vaccine Responses in Rheumatoid Arthritis Patients Using Tofacitinib. (23rd January 2014) Authors: Winthrop, K. L.; Neal, J.; Hrycaj, P.; Soma, K.; Wilkinson, B.; Hodge, J.; Zwillich, S. H.; Wang, T.; Rottinghaus, S.; Kawabata, T.; Riese, R.; Mebus, C.; Bradley, J. D.; Bingham, C. O. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. THU0131 Tofacitinib (CP-690, 550), an oral janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical programme. (23rd January 2014) Authors: Mariette, X.; Curtis, J.R.; Lee, E.B.; Riese, R.; Kaplan, I.; Chew, R.; Geier, J.; Wang, L.; Bradley, J.D. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0136 Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690, 550), a novel, oral jak inhibitor. (23rd January 2014) Authors: Charles-Schoeman, C.; Wicker, P.; Sechtem, U.; Gonzalez-Gay, M.A.; Wood, S.; Boy, M.; Geier, J.; Gruben, D.; Soma, K.; Riese, R.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. THU0140 Tofacitinib (CP-690, 550), an oral janus kinase inhibitor: Analysis of gastrointestinal adverse events across the rheumatoid arthritis clinical programme. (23rd January 2014) Authors: Lee, E.B.; Curtis, J.R.; Riese, R.; Connell, C.; Chew, R.; Boy, M.; Maller, E.; Su, C.; Wang, L.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗